ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "pulmonary"

  • Abstract Number: 2188 • ACR Convergence 2023

    Lung Cysts in Primary SS: New Findings on an Allegedly Innocuous Iiagnosis

    Regis Sewa Marques, Maria Fernanda Zacarin, Pamela Bellini, Raissa Dudienas D Pereira, Aloma Guinami Scabora, Zoraida Sachetto, Manoel Bertolo and ALISSON PUGLIESI, Universidade Estadual de Campinas, Campinas, Brazil

    Background/Purpose: Lung cysts are a frequent finding in patients with SS, with previous data indicating a prevalence of approximately 30% on chest CT scans. In…
  • Abstract Number: 0634 • ACR Convergence 2023

    Prevalence and Associations of Anaemia in Systemic Sclerosis Patients in a National Observational Cohort; Results from the Australian Scleroderma Cohort Study

    Raychel Barallon1, Gene-Siew Ngian1, Diane Apostolopoulos1, Dylan Hansen2, Kathleen Morrisroe3, Wendy Stevens4, Susanna Proudman5, Mandana Nikpour6 and Joanne Sahhar1, 1Monash Health and Monash University, Clayton, Australia, 2Department of Rheumatology, St Vincent’s Hospital Melbourne, Fitzroy, Australia, 3The University of Melbourne at St Vincent’s Hospital Melbourne, Fitzroy, Australia, 4Department of Rheumatology, St Vincent's Hospital Melbourne, Fitzroy, Australia, 5Royal Adelaide Hospital and University of Adelaide, Adelaide, Australia, 6The University of Melbourne at St. Vincent’s Hospital Melbourne, Departments of Medicine and Rheumatology, Melbourne, Australia

    Background/Purpose: Anaemia in systemic sclerosis (SSc) is under-studied and under-characterised. Its prevalence amongst SSc patients is not well described, nor are its effects on outcomes…
  • Abstract Number: 1699 • ACR Convergence 2023

    Immunosuppression with Targeted Therapies Reduces Morbidity and Mortality in Pre-Capillary Pulmonary Hypertension Associated with Systemic Sclerosis: A EUSTAR Analysis

    Cosimo Bruni1, Havard Fretheim2, Lorenzo Tofani3, Yannick Weber1, Eric Hachulla4, Patricia Carreira5, Dilia Giuggioli6, Paolo Airò7, Elise Siegert8, Ulf Müller-Ladner9, marco Matucci Cerinic10, Gabriela Riemekasten11, Carmen Pilar Simeon-Aznar12, Jeska de Vries-Bouwstra13, Lesley Ann Saketkoo14, Joerg Distler15, Alexandra Balbir-Gurman16, Ivan Castellvi17, Elisabetta Zanatta18, Vanessa Smith19, Christopher Denton20, Britta Maurer21, Alessandro Giollo18, Florenzo Iannone22, Lorenzo Dagna23, Marie-Elise Truchetet24, Masataka Kuwana25, Yannick ALLANORE26, Yoshiya Tanaka27, Mickael Martin28, Edoardo Rosato29, Ana Maria Gheorghiu30, Francesco Del Galdo31, Kamal Solanki32, Alessandra Vacca33, CATARINA RESENDE34, SUSANA VIEIRA35, Laszlo Czirjak36, Marko Barisic37, Francesco Paolo Cantatore38, valeria Riccieri39, Kristofer Andréasson40, Lorinda Chung41, Carolina Muller42, Daniela OPRIS-BELINSKI43, Simona Rednic44, Petros Sfikakis45, Yair Levy46, Anna Maria Hoffmann-Vold47, Oliver Distler1, Vivien Hsu48, Stefan Heitmann49, Gianluca Moroncini50, Michele Iudici51, Joerg Henes52, Ellen De Langhe53, Ariane Herrick54 and Carlomaurizio Montecucco55, 1Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, 2Oslo University Hospital, Oslo, Norway, 3Department of Statistics, Computer Science, Applications, University of Florence, Florence, Italy, 4University of Lille, Lille, France, 5Hospital Universitario 12 de Octubre, Madrid, Spain, 6Scleroderma Unit, Rheumatology Unit, University Hospital of Modena and Reggio Emilia, Modena, Italy, 7Spedali Civili di Brescia, Scleroderma UNIT, UOC Reumatologia ed Immunologia Clinica, Piazzale Spedali Civili 1, 25123, Brescia, Italy, 8Department of Rheumatology, Charité University Hospital, Charité Platz 1, D-10117, Berlin, Germany, 9Justus Liebig University Gießen, Campus Kerckhoff, Bad Nauheim, Germany, 10Unit of Immunology, Rheumatology, Allergy and Rare diseases, IRCCS San Raffaele Hospital, Milan, Milan, Italy, 11University Clinic Schleswit-Holstein (UKSH), Lübeck, Germany, 12Department of Internal Medicine, Systemic Autoimmune Diseases Unit, Hospital Universitario Vall d'Hebronh, Barcelona, Spain, 13Leiden University Medical Center, Leiden, Netherlands, 14University Medical Center - Comprehensive Pulmonary Hypertension Center and ILD Clinic Programs // New Orleans Scleroderma and Sarcoidosis Patient Care & Research Centeris, New Orleans, LA, 15Clinic for Rheumatology University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University, Düsseldorf, Germany; Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University, Düsseldorf, Germany, 16Rheumatology Institute, Rambam Health Care Campus and Rappaport Faculty of |Medicine, Technion, Haifa, Israel, 17Rheumatology, Hospital Universitari de la Santa Creu i Sant Pau, Sant Just Desvern, Spain, 18Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Padova, Padua, Italy, 19Ghent University Hospital, Gent, Belgium, 20University College London, London, United Kingdom, 21University Hospital Bern, University Bern, Bern, Switzerland, 22Rheumatology Unit, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari "Aldo Moro", Bari, Italy, 23Ospedale San Raffaele, Milano, Italy, 24Bordeaux University Hospital, Bordeaux, France, 25Nippon Medical School Graduate School of Medicine, Tokyo, Japan, 26Université Paris Cité, Paris, France, 27University of Occupational and Environmental Health, Kitakyushu, Japan, 28Department of Internal Medicine, INSERM U1313, Poitiers University, Poitiers University Hospital, Poitiers, France, 29Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy, 30Department of Internal Medicine and Rheumatology, Ion Cantacuzino Clinical Hospital, Bucharest, Romania, 31University of Leeds - Leeds Institute of Rheumatic and Muskuloskeletal Medicine, Leeds, United Kingdom, 32Department of Rheumatology, Te Whatu Ora Health New Zealand Waikato, Hamilton, New Zealand, 33II Chair of Rheumatology, University of Cagliari-Policlinico Universitario, Monserrato, Italy, 34Serviço de Reumatologia e Doenças Ósseas Metabólicas, Hospital de Santa Maria, CHLN, Lisboa, Portugal, 35Hospital Fernando Fonseca, Lisbon, Portugal, 36Dept. Rheumatol Immunol, Medical School, university of Pecs, Pecs, Hungary, 37Division of Clinical Immunology and Rheumatology, Department of Internal Medicine, University of Zagreb, School of Medicine, University Hospital Center Zagreb, Zagreb, Croatia, 38Rheumatology Clinic – Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy, 39Department of Clinical, Internal and Cardiovascular Specialities, Sapienza University of Rome, Roma, Italy, 40Lund University, Lund, Sweden, 41Department of Medicine, Division of Immunology and Rheumatology, Stanford University School of Medicine, Woodside, CA, 42Federal University of Parana, CURITIBA / PR, Brazil, 43Saint Mary Hospital, Bucharest, Romania, 44Prof Dr Simona Rednic, Cluj, Romania, 45National Kapodistrian University of Athens Medical School, Athens, Greece, 46Meir Medical Center, Autoimmune Research Laboratory, Kfar-Saba, Israel, 47Oslo University Hospital, Department of Rheumatology, Oslo, Norway, 48Rutgers-RWJ Medical School, South Plainfield, NJ, 49Department of Rheumatology, Marienhospital Stuttgart, Böheimstrasse 37, D-70199, Stuttgart, Germany, 50Marche Polytechnic University, Ancona, Italy, 51Division of Rheumatology, Department of Internal Medicine Specialties, Geneva University Hospitals, Geneva, Switzerland, 52University Hospital Tuebingen, Tuebingen, Germany, 53Division of Rheumatology, University Hospitals Leuven, Leuven, Belgium, 54University of Manchester, Salford, United Kingdom, 55Unità Operativa e Cattedra di Reumatologia, IRCCS Policlinico S Matteo, Pavia, Italy

    Background/Purpose: Systemic sclerosis (SSc) associated pre-capillary pulmonary hypertension (precapPH) is a severe condition that requires prompt treatment. Although immunosuppressants (IMS) are standard of care for…
  • Abstract Number: 2193 • ACR Convergence 2023

    Anti-citrullinated Protein Antibodies in Sjögren’s Syndrome Define a Subset of Patients with Lower B Cell Activation Markers and Higher Risk of Lung Involvement

    Augusto Silva1, Filipa Costa2, Mariana Silva2, Giovanni Fulvio3, Matilde Bandeira2, Manuel Silvério-António4, Nikita Khmelinskii2, Chiara Baldini3 and Vasco Romão2, 1Santa Maria Hospital, Maceira, Portugal, 2Centro Hospitalar Universitário Lisboa Norte, Lisboa, Portugal, 3University of Pisa, Pisa, Italy, 4Hospital Santa Maria, Lisboa, Portugal

    Background/Purpose: Extraglandular manifestations may occur in up to 40-50% of patients with SS, including inflammatory arthralgia and chronic polyarthritis (1-3). ACPA are prototypical markers of…
  • Abstract Number: 0637 • ACR Convergence 2023

    Comparison of Four Risk Stratification Models for Prediction of Mortality in Systemic Sclerosis-associated Pulmonary Arterial Hypertension in the EUSTAR Cohort

    Hilde Jenssen Bjørkekjær1, Cosimo Bruni2, Cathrine Brunborg3, Patricia Carreira4, Paolo Airò5, Carmen Pilar Simeon-Aznar6, Marie-Elise Truchetet7, Alessandro Giollo8, Alexandra Balbir-Gurman9, Mickael Martin10, Christopher Denton11, Armando Gabrielli12, Havard Fretheim13, Imon Barua13, Helle Bitter14, Oyvind Midtvedt13, Torhild Garen15, Kaspar Broch16, Arne Andreassen17, Yoshiya Tanaka18, Gabriela Riemekasten19, Ulf Müller-Ladner20, marco Matucci Cerinic21, Ivan Castellvi22, Elise Siegert23, Eric Hachulla24, Oliver Distler2 and Anna-Maria Hoffmann-Vold13, 1Department of Rheumatology, Hospital of Southern Norway, Kristiansand & University of Oslo, Institute of Clinical Medicine, Oslo, Norway, 2Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, 3Oslo Centre for Biostatistics and Epidemiology, Research Support Services, Oslo University Hospital - Rikshospitalet, Oslo, Norway, 4Hospital Universitario 12 de Octubre, Madrid, Spain, 5Spedali Civili di Brescia, Scleroderma UNIT, UOC Reumatologia ed Immunologia Clinica, Piazzale Spedali Civili 1, 25123, Brescia, Italy, 6Department of Internal Medicine, Systemic Autoimmune Diseases Unit, Hospital Universitario Vall d'Hebronh, Barcelona, Spain, 7Bordeaux University Hospital, Bordeaux, France, 8University of Verona, Rheumatology Section, Department of Medicine, Verona, Italy, Verona, Italy, 9Rheumatology Institute, Rambam Health Care Campus and Rappaport Faculty of |Medicine, Technion, Haifa, Israel, 10Department of Internal Medicine, INSERM U1313, Poitiers University, Poitiers University Hospital, Poitiers, France, 11University College London, London, United Kingdom, 12Ospedali Riuniti Marche, Ancona, Italy, 13Oslo University Hospital, Oslo, Norway, 14Sorlandet sykehus, Kristiansand, Norway, 15Dept of Rheumatology, University Hospital Oslo, Oslo, Norway, 16Oslo University Hospital, Rikshospitalet, Department of Cardiology, Oslo, Norway, KG Jebsen center, Institute for Experimental Medical Research, University of Oslo, Oslo, Norway, 17Oslo University Hospital, Rikshospitalet, Department of Cardiology, Oslo, Norway, 18University of Occupational and Environmental Health, Kitakyushu, Japan, 19University Clinic Schleswit-Holstein (UKSH), Lübeck, Germany, 20Justus Liebig University Gießen, Campus Kerckhoff, Bad Nauheim, Germany, 21Unit of Immunology, Rheumatology, Allergy and Rare diseases, IRCCS San Raffaele Hospital, Milan, Milan, Italy, 22Rheumatology, Hospital Universitari de la Santa Creu i Sant Pau, Sant Just Desvern, Spain, 23Department of Rheumatology, Charité University Hospital, Charité Platz 1, D-10117, Berlin, Germany, 24University of Lille, Lille, France

    Background/Purpose: The 2022 ESC/ERS Guidelines recommend comprehensive risk stratification at diagnosis of pulmonary arterial hypertension (PAH) to guide optimized management.1Several risk stratification tools have been…
  • Abstract Number: 1701 • ACR Convergence 2023

    Treatment Regimens and Mortality in Systemic Sclerosis-associated Pulmonary Arterial Hypertension in Light of the 2022 ESC/ERS Guidelines

    Hilde Jenssen Bjørkekjær1, Cosimo Bruni2, Cathrine Brunborg3, Patricia Carreira4, Paolo Airò5, Carmen Pilar Simeon-Aznar6, Marie-Elise Truchetet7, Alessandro Giollo8, Alexandra Balbir-Gurman9, Mickael Martin10, Christopher Denton11, Armando Gabrielli12, Havard Fretheim13, Imon Barua13, Helle Bitter14, Oyvind Midtvedt13, Torhild Garen15, Kaspar Broch16, Arne Andreassen17, Yoshiya Tanaka18, Gabriela Riemekasten19, Ulf Müller-Ladner20, marco Matucci Cerinic21, Iván Castellvi22, Elise Siegert23, Eric Hachulla24, Oliver Distler2 and Anna-Maria Hoffmann-Vold13, 1Department of Rheumatology, Hospital of Southern Norway, Kristiansand & University of Oslo, Institute of Clinical Medicine, Oslo, Norway, 2Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, 3Oslo Centre for Biostatistics and Epidemiology, Research Support Services, Oslo University Hospital - Rikshospitalet, Oslo, Norway, 4Hospital Universitario 12 de Octubre, Madrid, Spain, 5Spedali Civili di Brescia, Scleroderma UNIT, UOC Reumatologia ed Immunologia Clinica, Piazzale Spedali Civili 1, 25123, Brescia, Italy, 6Department of Internal Medicine, Systemic Autoimmune Diseases Unit, Hospital Universitario Vall d'Hebronh, Barcelona, Spain, 7Bordeaux University Hospital, Bordeaux, France, 8University of Verona, Rheumatology Section, Department of Medicine, Verona, Italy, Verona, Italy, 9Rheumatology Institute, Rambam Health Care Campus and Rappaport Faculty of |Medicine, Technion, Haifa, Israel, 10Department of Internal Medicine, INSERM U1313, Poitiers University, Poitiers University Hospital, Poitiers, France, 11University College London, London, United Kingdom, 12Ospedali Riuniti Marche, Ancona, Italy, 13Oslo University Hospital, Oslo, Norway, 14Sorlandet sykehus, Kristiansand, Norway, 15Dept of Rheumatology, University Hospital Oslo, Oslo, Norway, 16Oslo University Hospital, Rikshospitalet, Department of Cardiology, Oslo, Norway, KG Jebsen center, Institute for Experimental Medical Research, University of Oslo, Oslo, Norway, 17Oslo University Hospital, Rikshospitalet, Department of Cardiology, Oslo, Norway, 18University of Occupational and Environmental Health, Kitakyushu, Japan, 19University Clinic Schleswit-Holstein (UKSH), Lübeck, Germany, 20Justus Liebig University Gießen, Campus Kerckhoff, Bad Nauheim, Germany, 21Unit of Immunology, Rheumatology, Allergy and Rare diseases, IRCCS San Raffaele Hospital, Milan, Milan, Italy, 22Hospital de Santa Creu i Sant Pau, Barcelona, Spain, 23Department of Rheumatology, Charité University Hospital, Charité Platz 1, D-10117, Berlin, Germany, 24University of Lille, Lille, France

    Background/Purpose: The 2022 ESC/ERS Guidelines recommend upfront combination therapy for low- and intermediate-risk, and triple therapy for high-risk patients with systemic sclerosis (SSc)-associated pulmonary arterial…
  • Abstract Number: 2353 • ACR Convergence 2023

    Role of Insulin-like Growth Factor Binding Protein-7 (IGFBP7) in Pulmonary Hypertension Pathogenesis and as a Biomarker Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)

    Ye Jin Jeong1, Soumyaroop Bhattacharya1, Maria de la Luz Garcia-Hernandez2, Javier Rangel-Moreno1, Qingfu Xu3 and Benjamin Korman1, 1University of Rochester, Rochester, NY, 2University of Rochester, West Henrietta, NY, 3CanSino Biologic Inc., Tianjin, China

    Background/Purpose: Systemic sclerosis (SSc, scleroderma) is an autoimmune connective tissue disease that causes autoimmunity, vascular dysfunction, and fibrosis of the skin, lungs, and other organs.…
  • Abstract Number: 0638 • ACR Convergence 2023

    Application of the 2022 European Society of Cardiology (ESC) Risk Assessment Model in Australian and Singaporean Systemic Sclerosis Patients with Newly Diagnosed Pulmonary Arterial Hypertension (PAH)

    Zoe Brown1, Dylan Hansen2, Wendy Stevens3, Nava Ferdowsi4, laura ross5, Alannah Quinlivan6, Joanne Sahhar7, Gene-Siew Ngian7, Diane Apostolopoulos7, Jennifer G Walker8, Susanna Proudman9, Gim Gee Teng10, Andrea Hsiu Ling Low11, Kathleen Morrisroe12 and Mandana Nikpour13, 1The University of Melbourne, Armadale, Australia, 2Department of Rheumatology, St Vincent’s Hospital Melbourne, Fitzroy, Australia, 3Department of Rheumatology, St Vincent's Hospital Melbourne, Fitzroy, Australia, 4St Vincents Hospital, Kew, Australia, 5St. Vincent's Hospital Melbourne, Fitzroy, Australia, 6St Vincent's Hospital Melbourne, Highett, Australia, 7Monash Health and Monash University, Clayton, Australia, 8Royal Adelaide Hospital, Adelaide, Australia, 9Royal Adelaide Hospital and University of Adelaide, Adelaide, Australia, 10Alexandra Hospital, Department of Medicine, Division of Rheumatology, National University Health System, Singapore, Singapore, 11Department of Rheumatology and Immunology, Singapore General Hospital, Singapore, Singapore, 12The University of Melbourne at St Vincent’s Hospital Melbourne, Fitzroy, Australia, 13The University of Melbourne at St. Vincent’s Hospital Melbourne, Departments of Medicine and Rheumatology, Melbourne, Australia

    Background/Purpose: Pulmonary arterial hypertension (PAH) patients can be stratified as low, intermediate, or high risk of 1-year mortality based on clinical, biochemical and haemodynamic prognostic…
  • Abstract Number: 1704 • ACR Convergence 2023

    Esophageal Mucosal Erosions Can Predict the Deterioration of Lung Function over a Four-year Follow-up Period and Long-term Mortality in Patients with Interstitial Lung Disease Associated with Scleroderma

    gerlando Natalello1, enrico De Lorenzis1, Ludovica Berardini2, lucrezia verardi1, pier giacomo Cerasuolo1, Alfredo Papa3, Italo De Vitis3, Francesco Varone2, Luca Richeldi2, Maria Antonietta D'Agostino1 and Silvia Bosello1, 1Division of Rheumatology - Catholic University of the Sacred Heart, Fondazione Policlinico Universitario Agostino Gemelli, Rome, Italy, 2Division of Pulmonology - Catholic University of the Sacred Heart, Fondazione Policlinico Universitario Agostino Gemelli, Rome, Italy, 3Division of Gastroenterology - Catholic University of the Sacred Heart, Fondazione Policlinico Universitario Agostino Gemelli, Rome, Italy

    Background/Purpose: Interstitial lung disease (ILD) is a major cause of morbidity and disease-related death in systemic sclerosis (SSc). Esophageal disease is common in SSc, and…
  • Abstract Number: 2355 • ACR Convergence 2023

    Proteome-based Stratification of Therapeutic Target Population for MT-6194 in Systemic Sclerosis with Pulmonary Arterial Hypertension

    Yuuichi Ono1, Akira Mogami1, Ryuta Saito2, Noriyasu Seki1, Sho Ishigaki3, Hiroshi Takei3, Keiko Yoshimoto3, Kenji Chiba1, Tsutomu Takeuchi4 and Yuko Kaneko5, 1Mitsubishi Tanabe Pharma Corporation, Yokohama, Japan, 2Mitsubishi Tanabe Pharma Corporaion, Yokohama, Japan, 3Keio University School of Medicine, Tokyo, Japan, 4Keio University School of Medicine and Saitama Medical University, Tokyo, Japan, 5Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan

    Background/Purpose: SSc-related pulmonary arterial hypertension (SSc-PAH) is the one of the leading causes of death in SSc. Early diagnosis and effective therapy for SSc-PAH may…
  • Abstract Number: 0657 • ACR Convergence 2023

    The Value of the Six-Minute Walk Test in Detecting Cardiopulmonary Involvement in Patients with Systemic Sclerosis

    Saad Ahmed, Sophie Liem, Jeska de Vries-Bouwstra and Thomas Huizinga, Leiden University Medical Center, Leiden, Netherlands

    Background/Purpose: Cardiopulmonary involvement (CPI) in systemic sclerosis (SSc) is associated with significant morbidity and mortality. Early detection and timely treatment is warranted. The Six-minute walk…
  • Abstract Number: 1714 • ACR Convergence 2023

    Aberrant Myeloid Populations in the TNF-Transgenic Model of Pulmonary Hypertension Overexpress Interferon Pathways and Are Driven by TNFR1 Signaling

    Gaochan Wang1, Qingfu Xu2, Stacey Duemmel1 and Benjamin Korman1, 1University of Rochester, Rochester, NY, 2University of Rochester Medical Center, Rochester, NY

    Background/Purpose: Pulmonary hypertension (PH) is a severe, progressive disorder characterized by elevated pulmonary artery pressures, right ventricular hypertrophy, and increased mortality. We previously demonstrated that…
  • Abstract Number: 2364 • ACR Convergence 2023

    Circulating CTHRC1 Levels Are Associated with Disease Severity and Predict Survival in Systemic Sclerosis

    Monica Yang1, Seoyeon Lee2, Lisa Hazelwood3, Dean Sheppard1, Francesco Boin4 and Paul Wolters1, 1University of California San Francisco, San Francisco, CA, 2Yale University School of Medicine, New Haven, CT, 3AbbVie, Inc., North Chicago, IL, 4Cedars-Sinai Medical Center, Los Angeles, CA

    Background/Purpose: Despite recent advances in systemic sclerosis (SSc), there remains a paucity of clinically actionable biomarkers to assess disease severity and predict progression. Collagen triple…
  • Abstract Number: 0684 • ACR Convergence 2023

    Report on Twelve Patients with Diffuse Alveolar Hemorrhage in the Phase 3 Trial of Avacopan for the Treatment of ANCA-Associated Vasculitis

    Ulrich Specks1, David Jayne2 and Peter Merkel3, 1Mayo Clinic, Rochester, MN, 2University of Cambridge, Cambridge, United Kingdom, 3University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Although respiratory tract involvement in ANCA-associated vasculitis (AAV) is frequent and associated with increased mortality, studies focusing on diffuse alveolar hemorrhage (DAH) in AAV…
  • Abstract Number: 1718 • ACR Convergence 2023

    Longitudinal Quantification of Bone Erosions, Pulmonary Disease, Pain, Gait and Sarcopenia to Holistically Assess Decreased Ad Libitum Physical Activity and Effects of Exercise in the TNF-Transgenic Murine Model of Rheumatoid Arthritis

    Calvin Cole1, H. Mark Kenney2, Zachary Sechrist1, Yue Peng1, Kiana Chen3, Megan Falsetta1, Ronald Wood1, Homaira Rahimi4, Christopher T Ritchlin5 and Edward Schwarz4, 1University of Rochester Medical Center, Rochester, NY, 2University of Rochester School of Medicine and Dentistry, Henrietta, NY, 3University of Rochester School of Medicine and Dentistry, Rochester, NY, 4University of Rochester, Rochester, NY, 5University of Rochester Medical School, Allergy, Immunology & Rheumatology Division, Canandaigua, NY

    Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by pain, swelling, and joint destruction that decreases mobility.RA patients also suffer from pulmonary disease…
  • « Previous Page
  • 1
  • …
  • 4
  • 5
  • 6
  • 7
  • 8
  • …
  • 12
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology